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We evaluated the individual contributions of the three surface glycoproteins of human metapneumovirus (HMPV), namely the fusion F,
attachment G, and small hydrophobic SH proteins, to the induction of serum HMPV-binding antibodies, serum HMPV-neutralizing antibodies, and
protective immunity. Using reverse genetics, each HMPV protein was expressed individually from an added gene in recombinant human
parainfluenza virus type 1 (rHPIV1) and used to infect hamsters once or twice by the intranasal route. The F protein was highly immunogenic and
protective, whereas G and SH were only weakly or negligibly immunogenic and protective, respectively. Thus, in contrast to other paramyxoviruses,
the HMPVattachment G protein is not a major neutralization or protective antigen. Also, although the SH protein of HMPV is a virion protein that is
much larger than its counterparts in previously studied paramyxoviruses, it does not appear to be a significant neutralization or protective antigen.
Published by Elsevier Inc.Keywords: Human metapneumovirus; Neutralizing antibodies; Protective immunity; GlycoproteinIntroduction
Human metapneumovirus (HMPV), which was first des-
cribed in 2001 (van den Hoogen et al., 2001), is a member of
the Paramyxoviridae family and has been assigned to the
Metapneumovirus genus of the Pneumovirinae subfamily. This
subfamily also includes the Pneumovirus genus containing
respiratory syncytial virus (RSV). Like RSV, HMPV has been
found to infect humans worldwide and is a significant cause of
severe respiratory disease in infants and young children and
can infect and cause disease in older individuals as well
(Boivin et al., 2003; Osterhaus and Fouchier, 2003; Peret et
al., 2002). Like all members of the Paramyxovirus family,
HMPV is an enveloped, single-stranded, negative-sense RNA
virus. The genome is approximately 13 kb in length, and the
HMPV 3V to 5V gene order is N-P-M-F-M2-1/M2-2-SH-G-L,0042-6822/$ - see front matter. Published by Elsevier Inc.
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Metapneumovirus genus (Biacchesi et al., 2003; van den
Hoogen et al., 2002).
Sequence analysis of HMPV isolates indicates that there
are two major genetic lineages (Bastien et al., 2003;
Biacchesi et al., 2003) that are highly related antigenically
(Skiadopoulos et al., 2004), and the fusion F surface
glycoprotein has been identified as a major cross-protective
antigen (MacPhail et al., 2004; Skiadopoulos et al., 2004). In
addition to the F protein, all paramyxoviruses also have a
separate surface glycoprotein that is involved in attachment
and is called the G glycoprotein (subfamily Pneumovirinae),
the hemagglutinin H glycoprotein (genus Morbillivirus), or
the hemagglutinin–neuraminidase HN glycoprotein (all other
members of subfamily Paramyxovirinae). For other para-
myxoviruses examined to date, the F and G/H/HN surface
glycoproteins are the only significant neutralization antigens
and are major independent protective antigens (Chanock et
al., 2001). HMPV virions appear to have three surface
glycoproteins, namely the F (539 amino acids in length for
strain CAN83), G (219 amino acids), and small hydrophobic6) 492 – 501
www.e
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is much larger than its RSV counterpart (64–65 amino
acids). All three glycoproteins are incorporated into HMPV
virions (Biacchesi et al., 2004).
In the present study, we examined the relative contribution
of each of the three HMPV glycoproteins to inducing HMPV-
binding antibodies, HMPV-neutralizing antibodies, and pro-
tection against HMPV challenge. Recombinant human parain-
fluenza virus type 1 (rHPIV1) vectors were constructed that
individually express each of the HMPV surface glycoproteins.
These were used to immunize hamsters by the intranasal route
with either a single inoculation or with an additional booster
inoculation. Evaluation of the relative titers of serum antibodies
and protection conferred by each of the vectored HMPV
glycoproteins showed that the F glycoprotein was the major
contributor to induction of serum neutralizing antibodies and
protective immunity. Neither the G nor the SH protein induced
a detectable level of serum neutralizing antibodies, and the
contributions of G and SH to protection were minor or
negligible, respectively.
Results
Recovery of rHPIV1s containing an additional gene encoding
one of the HMPV surface glycoproteins
The relative contribution of each of the three HMPV
glycoproteins to the immunogenicity of HMPV was exam-
ined by separately expressing each protein from an additional
gene unit inserted into wild-type rHPIV1 by reverse genetics.
The full-length antigenomic HPIV1 cDNA was modified by
insertion of an additional gene unit consisting of the open
reading frame (ORF) for the HMPV strain CAN83 G or SH
protein flanked by HPIV1 transcription gene-start and gene-
end signal sequences (Fig. 1), as previously described for the
F gene insert (Skiadopoulos et al., 2004). cDNA constructs
with the G or SH ORF inserted into the pre-N ORF position
of the HPIV1 genome were unstable in bacteria; therefore,
gene units expressing these ORFs were inserted between the
P and M ORFs (Fig. 1), a position that has been shown to
also support a high level of expression in recombinant
HPIV3 (Durbin et al., 2000; Skiadopoulos et al., 2002).
Viruses were readily recovered and grew to high titer in
vitro. The growth kinetics of the rHPIV1s carrying each
additional gene unit were examined by multi-cycle growth in
LLC-MK2 cells (Fig. 2). The rHPIV1 vectors bearing the G
or SH gene unit grew to a similar titer and at a similar rate
as the rHPIV1 backbone virus. Surprisingly, the rHPIV1-F
grew at a moderately slower rate and to a lower peak virus
titer than either the backbone virus or the vector carrying the
G or SH gene. The basis for the reduced rate of growth for
rHPIV1-F is not known but might reflect the insert’s position
in the genome (von Messling et al., 2004), larger insert size
(Skiadopoulos et al., 2000), or the biological activity of the
F protein, which is fusogenic on its own without the
presence of its cognate attachment protein (Biacchesi et al.,
2004).Expression of the HMPV mRNAs and glycoproteins in vitro
To determine the relative level of mRNA produced by each
of the expression vectors in cell culture, Northern blot analysis
was performed on total intracellular RNA using dsDNA probes
against the HPIV1 HN mRNA (Fig. 3, panel A) and the HMPV
F, G, and SH mRNAs (panels B, C, and D). This showed that
the rHPIV1-F, -G, and -SH viruses expressed the HPIV1 HN
mRNA at approximately comparable levels, although that of
the rHPIV1-F virus was somewhat reduced, consistent with its
reduced growth efficiency. Each respective HMPV mRNAwas
expressed at a level that exceeded that present in HMPV-
infected cells (Fig. 3).
Expression of the HMPV glycoproteins from the respective
rHPIV1 vector was examined by indirect immunofluorescence
of infected LLC-MK2 monolayers, and each of the HMPV
glycoproteins was found to localize in the cell membrane (data
not shown), as expected for these surface glycoproteins.
Furthermore, sucrose purified rHPIV1-G was found to contain
a high level of HMPV G protein incorporated into the viral
particles (data not shown). Incorporation of the HMPV F or SH
glycoproteins into rHPIV1 virus particles could not be
detected; however, SH protein produced from the rHPIV1-
SH expression vector was incorporated into HMPV D-SH (an
HMPV mutant containing a deletion of the SH ORF; Biacchesi
et al., 2004) virus particles in a co-infection of LLC-MK2 cells
(data not shown). Western blot analysis was performed to
determine the level of expression in cell culture of each HMPV
glycoprotein by its respective rHPIV1 vector compared to
HMPV (Fig. 4). The HMPV F and G proteins could be
detected in total cell lysates using an antiserum raised against
HMPV (Fig. 4, panel A), whereas detection of the SH protein
required in addition the use of an antipeptide antiserum and
even then was inefficient (panel B). Densitometer quantifica-
tion of the respective F, G, and SH protein bands was
performed and, in each case, the relative level of each
glycoprotein expressed from either rHPIV1 or HMPV was no
more than two-fold different (data not shown). The SH protein
was poorly expressed in rHPIV1-SH-infected cells, but this
also is the case in HMPV-infected cells. Thus, the level of
expression of each HMPV glycoprotein was similar between
the rHPIV1 vectors and HMPV (Fig. 4).
Replication in hamsters
To evaluate the level of replication of the rHPIV1 vectors in
the upper and lower respiratory tract of hamsters, groups of
hamsters were immunized intranasally (IN) with each recom-
binant, the lungs and nasal turbinates were harvested after 4
days, and the titer of virus present in tissue homogenates was
determined. The rHPIV1 vectors expressing the HMPV
glycoproteins replicated as efficiently as the rHPIV1 parent
virus in the nasal turbinates and only about 10-fold less
efficiently in the lungs (Fig. 5). The comparable levels of
replication of rHPIV1-F, rHPIV1-G, and rHPIV1-SH in
hamsters made it possible to directly compare their immuno-
genicity and protective efficacy.
Fig. 1. Construction of rHPIV1 vectors expressing the F, G, or SH protein of HMPV. (A) Wild-type rHPIV1 genome (not to scale) with introduced MluI and NotI
restriction sites (underlined). Each of the six rHPIV1 gene units is drawn as an open rectangle flanked by transcription gene start (grey rectangle) and gene end (black
rectangle) sequence motifs. (B) Construction of the gene unit expressing the HMPV F protein. The upper diagram shows a PCR-engineered DNA that was inserted
into the MluI site of the rHPIV1 vector (bottom diagram), placing the HMPV F gene unit upstream of the N ORF, as described previously (Skiadopoulos et al.,
2004). Four additional nucleotides (R6) were inserted to maintain the polyhexameric length of the genome (Calain and Roux, 1993) and to maintain the phasing of
the position of the gene start signals (Kolakofsky et al., 1998), as also was done for the constructs shown in panels C and D. (C) Construction of the gene unit
expressing the HMPV G protein. G ORF of HMPV strain CAN83 (GenBank accession number AY297749) (660 nucleotides in length and encoding a 219-amino-
acid polypeptide) was engineered by PCR to be preceded by the indicated HPIV1 transcription gene end, intergenic, and gene start signal sequence (top diagram).
Insertion of this engineered DNA into the NotI site placed the G-encoding gene unit between the HPIV1 P and M genes. (D) Construction of the gene unit expressing
the HMPV SH protein. The HMPV strain CAN83 SH ORF (540 nucleotides in length and encoding a 179-amino-acid protein) was engineered by PCR to be
preceded by the indicated HPIV1 transcription signals and was inserted into the NotI restriction site between the HPIV1 P and M ORFs, as described above for the
HMPV G ORF. (E) Schematic representation (not to scale) of the three recombinant HPIV1 each containing an added gene unit encoding the HMPV F, G, or SH
glycoprotein ( ).
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To evaluate the immunogenicity of the individual HMPV
glycoproteins, groups of hamsters were infected intranasally
with rHPIV1-F, rHPIV1-G, rHPIV-SH, HMPV, or rHPIV1
(Table 1). After 30 days, each group of hamsters was either
reinfected with a second, higher dose (see Table 1) of the
vector carrying the homologous HMPV glycoprotein or with
the rHPIV1 vector backbone alone. Serum was collected
before the first infection and 26 days after the second infection
(day 56). The animals were challenged IN with HMPV 28
days after the second infection (day 58). Thus, this experimentevaluated and compared the immunogenicity and protective
efficacy of one or two doses of each rHPIV1-vectored HMPV
glycoprotein.
The titers of serum antibodies capable of binding HMPV
antigen were determined by ELISA using HMPV-infected
LLC-MK2 cells as the solid phase antigen, with binding
quantified using an indirect immunoperoxidase assay (Table 1).
As a control, the titers of serum antibodies capable of
neutralizing HPIV1 were determined; these were found to be
similar for the different rHPIV1 vectors, indicating that the
immunogenicity of the vectored HMPV F, G, and SH antigens
could be compared. Animals receiving one or two doses of the
Fig. 2. Replication of rHPIV1-F, -G, or -SH viruses in vitro. LLC-MK2 cell
monolayers were infected in triplicate at an m.o.i. of 0.01 with the rHPIV1
parent and HPIV1 vectors, as indicated, and the monolayers were incubated at
32 -C. Aliquots of the medium supernatants were harvested at 24-h intervals,
flash-frozen, and subsequently assayed at 32 -C for virus titer. Virus titers are
expressed as mean log10 TCID50/ml T standard error.
Fig. 3. Northern blot analysis. LLC-MK2 cells were infected at an m.o.i. of 1.0
with the rHPIV1 parent, the rHPIV1 vectors, HMPV, or were mock-infected, as
indicated, and harvested after 48 h. 1 Ag of purified total RNA for each
indicated sample was separated by denaturing agarose gel electrophoresis and
analyzed by Northern blot hybridization with the indicated radiolabeled dsDNA
probes.
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titer (approximately 1:1000) of HMPV-binding serum anti-
bodies, a titer comparable to that obtained following infection
with wild-type HMPV (Table 1). However, two doses of
rHPIV1-G resulted in approximately one-tenth the titer of
HMPV-binding antibodies compared to that induced by a
single immunization with rHPIV1-F (Table 1). Two immuniza-
tions with the vector expressing the HMPV-SH protein did not
induce detectable HMPV-binding antibodies (Table 1) despite
expression of the SH protein by rHPIV1. The binding assay
was capable of detecting SH-specific antibodies raised in
rabbits against a synthetic peptide of SH, indicating that there
was sufficient SH antigen in the infected cell monolayer, and
that the lack of detectable anti-SH antibodies in the serum of
immunized animals was not due to a limitation of the assay
(data not shown). The SH protein of RSV has also been found
to be poorly immunogenic (Connors et al., 1991). Thus, the F
protein of HMPV is highly immunogenic in hamsters and is
significantly more immunogenic than the G protein, whereas
the SH protein is very poorly immunogenic.
The ability of rHPIV1-F, -G, or -SH to induce neutralizing
antibodies and resistance to HMPV challenge was next
determined. One or two immunizations with rHPIV1-F induced
a high level of serum neutralizing antibodies to HMPV,
confirming previous observations (Skiadopoulos et al., 2004;
Tang et al., 2003), and this correlated with a significant level of
protection in the upper respiratory tract and complete protection
in the lower respiratory tract of immunized animals (Table 1).
Two doses of rHPIV1-F induced a greater level of reduction in
HMPV virus challenge replication in the nasal turbinates than
one dose (2.8 log10 reduction versus 1.8 log10, respectively).
However, even two doses of rHPIV1-F did not induce as much
protection as infection with a single dose of wild-type HMPV
(4.6 log10 reduction). In preliminary experiments, immunization
of hamsters with a single dose of rHPIV1-G or rHPIV1-SH
followed by challenge with HMPV 30 days post-infection did
not confer protection (data not shown). We therefore examined
the ability of two doses of the G and SH protein expression
vectors to confer neutralizing antibodies or protection against
HMPV challenge. Immunization with rHPIV1-SH did notinduce detectable neutralizing antibodies and the animals were
not protected when challenged with HMPV (protection is
defined as being a reduction in challenge HMPV replication
of 1.0 log10 or greater) (Table 1). One or two doses of rHPIV1-G
also did not induce a detectable level of serum neutralizing
antibodies, which was surprising since ELISA binding anti-
bodies were induced. Animals immunized once with rHPIV1-G
were not protected from HMPV challenge. However, animals
that were immunized twice with the HPIV1-G recombinant were
partially protected from HMPV challenge in both the nasal
turbinates and the lungs, although reduction in challenge virus
replication was statistically significant only in the nasal
turbinates (Table 1). Since neutralizing antibodies were not
produced even after the second immunization with rHPIV1-G,
it is possible that the low level of protection against HMPV
challenge observed after two doses might be mediated by
some other immune mechanism, such as HMPV-specific
CD8+ T-cells.
Discussion
Recombinant HPIV1 was used as an intranasal vector to
compare the relative levels of immunogenicity and protective
efficacy of the HMPV F, G, and SH proteins. The HMPV F
protein had previously been shown to be a neutralization and
protective antigen, but the status of G or SH was not known. In
particular, while the SH protein of RSV does not appear to be a
significant neutralization and protective antigen, the HMPV SH
protein is nearly 2.5 times larger and thus should present a
significant target on the surface of infected cells and the virus
particle. The results confirmed that HMPV F is a major
antigen, but surprisingly showed that neither G nor SH induced
detectable serum HMPV-neutralizing antibodies even after a
Fig. 4. Western blot analysis. LLC-MK2 cells were infected at an m.o.i. of 1.0 with the rHPIV1 parent, the rHPIV1 vectors, HMPV, or were mock-infected, as
indicated, and harvested after 48 h. An equivalent amount of cell lysate for each indicated sample was separated by SDS-PAGE. SDS-PAGE and Western blot
analysis were performed using (A) non-reducing conditions and hamster anti-HMPV antibodies or (B) reducing conditions and a mixture of rabbit anti-HMPV and
anti-SH peptide antibodies, followed by a peroxidase labeled secondary antibody. The Fm (multimeric form of F) and F1/F2 (heterodimeric form of F) and G protein
bands are boxed in panel A, and the SH protein bands are boxed in panel B. HMPV protein bands are indicated adjacent to the HMPV lanes.
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protective response against HMPV challenge, while that of SH
was insignificant.
The finding that the putative HMPV attachment G protein
did not induce a significant response of serum HMPV-
neutralizing antibodies and was poorly protective differs from
observations obtained with all other paramyxoviruses evalua-
ted to date. The attachment G, H, or HN proteins of other
paramyxovirus have been found to stimulate high levels of
ELISA antibodies (Paterson et al., 1987; Schmidt et al., 2001).
In the case of RSV, the human paramyxovirus most closely
related to HMPV, the F and G proteins each induce binding and
neutralizing antibodies and protect rodents and non-human
primates against RSV challenge after a single dose (Olmsted et
al., 1986; Schmidt et al., 2001, 2002). In rodents and non-
human primates, the F protein of RSV afforded a higher level
of protection in the upper and lower respiratory tract compared
to the animals immunized with the G protein indicating that F
is the greater protective antigen for RSV seronegative animals
(Olmsted et al., 1986; Schmidt et al., 2001, 2002). However, in
those studies, the RSV G protein induced a significant level of
neutralizing antibodies and was very protective against RSVFig. 5. Replication in hamsters. Hamsters were inoculated i.n. with 106 TCID50 of th
group were harvested on day four post-infection. Virus present in tissues was quantif
mean virus titer (log10 TCID50/g) for the group.challenge. In the case of HPIV3, the HN protein, which is the
counterpart of the G protein of RSV and HMPV, was found to
be the predominant HPIV3 protective antigen, although the
HPIV3 F protein also induced neutralizing antibodies (Spriggs
et al., 1987). Mice were protected from infection with murine
PIV1 (Sendai virus) by prior immunization with a vaccinia
virus expressing the Sendai virus F or HN glycoprotein (Takao
et al., 1997), but not with other viral proteins (Sakaguchi et al.,
1993). For simian virus 5 (SV5), the F protein is more
immunogenic than the HN protein, but both the SV5 F and HN
proteins expressed by vaccinia recombinants protected equally
against homologous challenge (Paterson et al., 1987). Thus,
unlike these and other paramyxoviruses characterized to date,
HMPV is unique in that only the F protein contributes to the
induction of neutralizing antibodies and provides most of the
protection against homologous challenge.
The basis for the difference in immunogenicity between the
three HMPV surface glycoproteins is not known, but the
difference is striking. Both the F and G mRNAs and proteins
were expressed well in tissue culture, suggesting that the
difference in their immunogenicity is not simply a factor of a
difference in their level of expression. The SH mRNA also wase indicated virus. Nasal turbinates and lung tissues from six animals from each
ied by serial dilution on LLC-MK2 monolayers at 32 -C and is expressed as the
Table 1
Immunogenicity and protective efficacy of the HMPV F, G, or SH glycoprotein expressed individually by a recombinant HPIV1 vector administered intranasally in
one and two doses
No. of Immunization Serum neutralizing antibody Serum binding antibody Replication of challenge HMPV in the indicated tissuesc
animals
Firstd
(day 0)
Seconde
(day 30)
titer (recip. mean log2 T SE)
on day 56 to the indicated virusa
titer (recip. mean
log2 T SE) to HMPV
b Nasal turbinates Lungs
HPIV1 HMPV
on day 56 Titer (log10
TCID50/g T SE)
Reduction in
titer (log10)
f
Titer (log10
TCID50/g T SE)
Reduction in
titer (log10)
f
5 HMPV rHPIV1 3.3 T 0.3 7.8 T 0.3 10.3 T 0.0 1.5 T 0.0g 4.6 1.5 T 0.0g 1.9
6 rHPIV1-F rHPIV1-F 3.9 T 0.3 8.3 T 0.4 10.0 T 0.4 3.3 T 0.2g 2.8 1.5 T 0.0g 1.9
6 rHPIV1-F rHPIV1 5.5 T 0.3 8.3 T 0.3 9.9 T 0.4 4.3 T 0.3g 1.8 1.5 T 0.0g 1.9
6 rHPIV1-G rHPIV1-G 5.4 T 0.4 2.9 T 0.0 7.5 T 0.9 4.6 T 0.5h 1.5 2.4 T 0.4i 1.0
6 rHPIV1-G rHPIV1 4.7 T 0.1 2.9 T 0.0 5.9 T 1.0 5.3 T 0.3 0.8 2.7 T 0.4 0.7
6 rHPIV1-SH rHPIV1-SH 4.8 T 0.3 2.9 T 0.0 2.9 T 0.0 5.3 T 0.2 0.8 2.7 T 0.1 0.7
6 rHPIV1-SH rHPIV1 5.4 T 0.3 2.9 T 0.0 2.9 T 0.0 6.0 T 0.1 0.1 3.1 T 0.2 0.3
8 rHPIV1 rHPIV1 5.3 T 0.3 2.9 T 0.0 2.9 T 0.0 6.1 T 0.2 – 3.4 T 0.2 –
a Sera collected 26 days following the second immunization (day 56) were used in a neutralization assay. The titer is expressed as the mean reciprocal log2 T
standard error.
b Sera collected 26 days following the second immunization (day 56) were tested for the ability to detect HMPV-infected LLC-MK2 cells by indirect
immunoperoxidase staining. The mean serum binding antibody titer is the highest dilution of antibody at which the cultures were positive for infection, as determined
by immunoperoxidase staining.
c Twenty-eight days after the second immunization (day 58), the hamsters were challenged IN with 105.7 TCID50 of HMPV. Four days after challenge, the nasal
turbinates and lungs were harvested and tissue homogenates were prepared. Virus present in the tissue homogenates was quantified by serial terminal dilution on
LLC-MK2 monolayers and is expressed as the geometric mean log10TCID50/g for each group T standard error.
d Groups of 5 to 8 HMPV- and HPIV1-seronegative (mean reciprocal serum neutralizing titer 1.0 log2) hamsters were immunized IN with 106 (rHPIV1 and
rHPIV1 vectors) or 105 (HMPV) TCID50 of the indicated virus on day 0.
e Thirty days following the first immunization, the indicated groups received a second IN immunization with 106.4 (rHPIV1-F, rHPIV1-SH, or rHPIV1) or 107.4
(rHPIV1-G) TCID50 of the indicated virus.
f Reduction in titer compared to group that was immunized only with rHPIV1.
g Statistically significant difference between this group and animals that received only rHPIV1; P < 0.001 (Tukey–Kramer Multiple Comparison Test).
h Statistically significant difference between this group and animals that received only rHPIV1; P < 0.01 (Tukey–Kramer Multiple Comparison Test).
i Statistically significant difference between this group and animals that received only rHPIV1; P < 0.05 (Tukey–Kramer Multiple Comparison Test).
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protein appeared to be relatively lower than that of F and G in
both rHPIV1-SH- and HMPV-infected cells. However, it is
uncertain if the present lack of good antibodies to detect this
protein may be a factor in its apparent lower abundance in
Western blot analysis. Consequently, one factor for the low
level of binding and neutralizing antibodies induced by SH
may be its relatively lower abundance in an infection. Another
factor could be the relative level of glycosylation of these
proteins. The HMPV G and SH proteins are heavily
glycosylated compared to the F protein (Biacchesi et al.,
2004), and it has been suggested that a high level of
glycosylation may affect the immunogenicity of certain
proteins (Komada et al., 2000). However, the RSV G
glycoprotein is heavily glycosylated yet induces a high level
of neutralizing antibodies. The observation in the present study
that the moderate level of antibodies against G detected in a
binding assay did not neutralize infectivity is remarkable
because G is presumed to play an important role in
paramyxovirus attachment, and antibodies against attachment
proteins generally have neutralizing activity. For RSV, the G
protein is essential for replication in vivo (Teng and Collins,
2002; Teng et al., 2001). Recently, it was observed that G and
SH could be deleted from recombinant HMPV with minimal or
no effect, respectively, on growth in vitro and in vivo
(Biacchesi et al., 2004, 2005a). Therefore, these proteins might
be weak neutralization and protective antigens because, inaddition to being poorly immunogenic, they lack absolutely
essential roles in virus infection and replication.
The formal possibility exists that the HMPV F and G
proteins might need to be expressed together in order for the G
protein to be both immunogenic and protective. However, this
would be without precedent among the paramyxoviruses, since
all of the F and G/H/HN proteins examined to date have been
independent neutralization and protective antigens. Further-
more, sera of wild caught African green monkeys found to be
seropositive for HMPV, and sera of monkeys experimentally
infected with HMPV, where both the F and G proteins are
expressed concurrently, recognize the HMPV F protein
exclusively (Western blot analysis of virion proteins, data not
shown and Biacchesi et al., 2005b). These observations are
consistent with the present findings that the F protein is the
major immunogenic surface protein of HMPV whereas G and
SH are poorly immunogenic. These observations, together with
the finding that HMPV F can confer protection against both
genetic lineages of HMPV (Skiadopoulos et al., 2004), have
implications for the formulation of a live-attenuated HMPV
vaccine. Specifically, they provide support for the strategy of
attenuating HMPV by deletion of the G gene (Biacchesi et al.,
2004), given the minimal role of the G protein in protective
immunity, its loss should not significantly reduce vaccine
immunogenicity and efficacy.
In addition, the F protein is clearly the protein of choice for
inclusion in a vectored HMPV vaccine, following the
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as a vector to express protective antigens of additional
pathogens such as HMPV or RSV to make bivalent or
multivalent pediatric vaccines (Schmidt et al., 2001, 2002).
However, it should be noted that, in the present study and in
previous studies using other vectored paramyxovirus antigens,
the protection afforded by vectors expressing individual
proteins was not as complete as that conferred by infection
with the wild-type virus. This was true in the present study
despite the administration of two doses of rHPIV1-F versus a
single dose of HMPV. Incomplete protection occurred in
rHPIV1-F-immunized animals despite the induction of a level
of HMPV-neutralizing antibodies that was essentially identical
to that of the HMPV-immunized animals. In contrast, a single
dose of a live-attenuated rHMPV virus with a deletion (D) in G
or M2-2 coding sequences induced a higher level of resistance
to HMPV challenge than did two doses of rHPIV1-F
(Biacchesi et al., 2005a). This was so despite the fact that
rHPIV1-F replicated to almost wild-type HPIV1 levels in
hamsters, which should achieve maximum immunogenicity,
whereas the replication of the HMPV DG and DM2-2 viruses
was highly restricted. Previously, we observed a similar
phenomenon in animals immunized with HPIV3 vectors
expressing the HN protein of HPIV1 and HPIV2 (Skiadopou-
los et al., 2002). Vector-immunized animals that were
subsequently challenged with HPIV1 or HPIV2 were signifi-
cantly protected, but the protection was not as effective as that
induced by previous infection with the complete homologous
virus. In another study, a chimeric bovine-human PIV3 vector
expressing the HMPV NL/1/00 strain F protein also did not
confer complete protection in HMPV challenged African green
monkeys (Tang et al., 2005). These findings indicate that,
although vectored vaccines may be useful in inducing
neutralizing and protective antibodies, immunization with the
whole virus will likely be a more effective strategy. In the
present study, since two doses of rHPIV1-F induced a
comparable level of neutralizing antibodies to HMPV as
infection with wild-type HMPV but a lower level of protection,
it is likely that other HMPV proteins also contributed to
protection, possibly by inducing HMPV-specific CD8+ T-cells.
Previous studies of the contribution of the internal proteins of
HPIV3 to protective immunity in hamsters clearly indicated
that such antigens play an important role in resistance (Tao et
al., 2000), and the findings from the present study suggest that
this might be true for HMPV as well.
Materials and methods
Cell lines and viruses
Rhesus monkey kidney cells (LLC-MK2; ATCC CCL 7.1)
were maintained in OptiMEM (Invitrogen, Grand Island, NY)
supplemented with 5% FBS and gentamicin sulfate (50 Ag/ml).
HMPV strain CAN97-83, kindly provided by Guy Boivin
(Peret et al., 2002), is a clinical isolate that was propagated in
LLC-MK2 cells. The recombinant HPIV1 strains Wash/64 and
HMPV were grown in LLC-MK2 cells in the presence of 5 Ag/ml added porcine derived trypsin (BioWhittaker, Walkersville,
MD), as described previously (Biacchesi et al., 2003; Newman
et al., 2002; Skiadopoulos et al., 2004). Virus pools were
generated, and virus titers were determined at 32 -C in LLC-
MK2 cells grown in OptiMEM medium and supplemented
with 5 Ag/ml added trypsin. Viral titers were quantified by
serial 10-fold dilution of virus applied to LLC-MK2 monolayer
cultures on 96-well plates (Costar, Corning, NY). Infected
cultures were incubated for 7 to 8 days at 32 -C in OptiMEM
medium with 5 Ag/ml added trypsin. HMPV-infected mono-
layers were detected by incubation with hamster polyclonal
HMPV antiserum (see below) used at a 1:500 dilution,
followed by a second antibody (1:250 dilution) consisting of
peroxidase-conjugated rabbit anti-Syrian hamster IgG (Jackson
Immunochemicals, West Grove PA). Bound antibody–antigen
complexes were detected by immunoperoxidase staining
achieved with ECL chromogenic substrate (KPL, Gaithersburg,
MD). HPIV1-infected cultures were detected by hemadsorption
with guinea pig erythrocytes, as described previously (Newman
et al., 2002). The virus titers are reported as log10TCID50/ml
(50% tissue culture infectious dose/ml).
Generation of recombinant HPIV1s expressing the HMPV G or
SH protein
The full-length antigenomic HPIV1 cDNA (Newman et al.,
2002) (GenBank accession number AF457102) had been
previously modified by nucleotide substitutions to create a
unique MluI site at nucleotides 113–118, which was used as
the insertion site for the HMPV F gene unit for the recovery of
recombinant HPIV1 expressing the HMPV F protein
(rHPIV1-F) (Skiadopoulos et al., 2004). The antigenomic
cDNA containing the MluI site was further modified at
nucleotides 3609–3616 (GCTCCCTC) to create a unique
cloning site (NotI; GCGGCCGC) immediately downstream of
the P protein open reading frame (ORF). The HMPV G protein
and SH protein ORFs (GenBank accession no. AY297749)
were amplified from purified HMPV strain CAN97-83 vRNA
and each was modified to contain the flanking HPIV1
cis-acting gene start and gene end transcription signals
indicated in Fig. 1. The recombinant HPIV1 expressing the
G or SH proteins (rHPIV1-G and rHPIV1-SH, respectively)
was recovered from transfected HEp-2 cells as described
previously (Newman et al., 2002). Recovered viruses were
biologically cloned and amplified in LLC-MK2 cells as
described previously (Newman et al., 2002).
Growth kinetics of rHPIV1 vectors in vitro
The kinetics of replication of the rHPIV1 vectors was
determined by their inoculation, in parallel with the rHPIV1
parent, onto LLC-MK2 monolayers in 6-well plates (Costar;
Corning, NY) at a multiplicity of infection (m.o.i.) of 0.01. The
cultures were incubated at 32 -C in the presence of 5 Ag/ml
added trypsin, and 0.5 ml of medium from each well was
harvested and replaced with 0.5 ml of fresh OptiMEM medium
supplemented with trypsin (5 Ag/ml) at 0 h and at 24 h intervals
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and virus titers were subsequently determined by titration on
LLC-MK2 monolayers in 96-well plates as described above.
Northern blot analysis
LLC-MK2 cells were mock-infected or infected with
HMPV, rHPIV1, rHPIV1-F, rHPIV1-G, or the rHPIV1-SH
virus, each at an input m.o.i. of 1 TCID50 per cell, incubated for
2 days at 32 -C in the presence of trypsin (5 Ag/ml), and
processed to purify total intracellular RNA using an RNeasy kit
(QIAGEN, Valencia, CA) according to the manufacturer’s
instructions. Equivalent amounts of total RNA from each
sample were electrophoresed in a 1% agarose gel in the
presence of 0.44 M formaldehyde, transferred to a charged
nylon membrane (Hybond-N; Amersham Biosciences, Bucks,
UK), fixed by UV cross-linking, and analyzed by hybridization
with denatured double-stranded 32P-labeled DNA probes
generated by random priming from HMPV F, SH, or G, or
rHPIV1 HN cDNA fragments (Megaprime DNA labeling
system; Amersham Biosciences, Piscataway, NJ). Radioacti-
vity was detected by analysis with a Phosphorimager (Molec-
ular Dynamics Inc., Sunnyvale, CA).
Protein electrophoresis and Western blot assay
Aliquots of infected cell lysates were reduced and denatured
by heating at 99 -C for 5 min and analyzed on a 4-to-12%
polyacrylamide Bis-Tris gel (NuPAGE Novex Bis-Tris; Invi-
trogen, Carlsbad, CA). The separated proteins were electro-
transferred onto a polyvinylidene difluoride membrane
(Invitrolon; Invitrogen). The membrane was blocked overnight
at 4 -C in Western blocking reagent (Roche, Indianapolis, IN).
HMPV F and G were detected under non-reducing conditions,
using a hyperimmune serum produced by immunization of
hamsters with HMPV (Skiadopoulos et al., 2004). HMPV SH
was detected under reducing conditions with a cocktail of
rabbit anti-HMPV antibodies and a rabbit antiserum raised
against peptide SH 82–96, representing aa 82 to 96 of SH.
Bound antibodies were visualized by binding with horseradish
peroxidase-conjugated goat anti-rabbit or anti-hamster immu-
noglobulin G antibodies (Kirkegaard and Perry Laboratories,
Gaithersburg, Md.) followed by chemiluminescence (Super-
Signal West Pico chemiluminescent substrate; Pierce, Rock-
ford, IL). Western blot autoradiographies were scanned using a
densitometer (Personal Densitometer SI; Molecular Dynamics)
to quantify HMPV proteins.
Neutralization and binding assays
The susceptibility of HMPV or rHPIV1 to neutralization by
serum antibodies from immunized hamsters was determined
using an endpoint dilution neutralization assay. For HMPV
neutralization assays, 75 Al aliquots of OptiMEM containing
approximately 200 TCID50 of HMPV were mixed with equal
aliquots of OptiMEM containing serial two-fold dilutions of
hamster serum that had been heat inactivated at 56 -C for 30min.The virus–antibodymixtures were incubated at 37 -C for 1 h. 50
Al of each virus–antibody mixture was then transferred to each
of two wells of a 96-well plate containing LLC-MK2 cells and
incubated for approximately 1 h at 32 -C. The virus–antibody
mixture was removed, and the monolayers were washed twice
with OptiMEM. 180 Al OptiMEM supplemented with trypsin
was added to the cultures, which were incubated at 32 -C for
8 days and supplementedwith additional trypsin (250 ng in 50 Al)
on day 6. Infected cultures were detected by immunoperoxidase
staining using polyclonal hamster anti-HMPV serum, as
described above. The neutralization titer is the highest dilution
of antibody at which half of the cultures were negative for
infection.
The level of serum HPIV1 neutralizing antibodies was
determined using a complement-enhanced assay. Two-fold
serial dilutions of hamster serum were combined with an equal
volume of virus suspension containing approximately 104.9
TCID50 of rHPIV1modified to express green fluorescent protein
(rHPIV1-GFP) that served as the indicator virus as described
previously (Bartlett et al., 2005). The virus and serum mixture
was incubated at 37 -C for 1 h in MEM (Gibco-Invitrogen, Inc.)
and 10% guinea pig complement (Cambrex Inc., Walkerville,
MD) and was transferred to LLC-MK2 monolayers in 96-well
plates. After a 1 h adsorption period, the monolayers were
washed three times to remove residual serum and complement,
and OptiMEM I containing trypsin was added. Infected
monolayer cultures were incubated at 32 -C for 7 days, and
read for GFP expression on the Typhoon phosphorimager using
a Typhoon 8600 scanner (Molecular Dynamics Inc.) control
program (settings: fluorescence; filter, 526-SP green fluoresce-
in). The end-point was defined as the highest dilution of the
serum/virus mixture that exhibited 50% reduction in the level
of GFP expression. The neutralization titer is the highest dilution
of serum at which 50% of the wells exhibited50% reduction in
GFP expression, determined using the IPLab Gel program
(Signal Analytics Corp., Vienna, VA).
The HMPV binding assay determined the ability of serial
two-fold dilutions of hamster serum antibodies to bind to
HMPV-infected LLC-MK2 monolayer cultures. LLC-MK2
monolayers in 96-well cell culture plates were infected with
103.5 TCID50 HMPV/well. The infected cultures were incuba-
ted at 32 -C for 7–8 days. Cells were fixed with 80% methanol
for 10 min and were blocked with 5% skim milk powder in
PBS for 1 h. Infected cell cultures were identified by indirect
immunoperoxidase staining with serial two-fold dilutions of
hamster serum followed by peroxidase-conjugated anti-hamster
antibodies (Jackson Immunochemicals). The binding titer is the
highest dilution of serum at which 50% of the wells were
positive for infection by peroxidase staining.
Determination of replication of rHPIV1 vectors and protective
efficacy in hamsters
Groups of six 4-week-old Golden Syrian hamsters were
inoculated intranasally with 0.1 ml of L15 medium containing
106 TCID50 of rHPIV1-F, rHPIV1-G, rHPIV1-SH, or rHPIV1.
On day 4 post-infection, the lungs and nasal turbinates were
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of individual specimens was quantified by serial dilution of
tissue homogenates on LLC-MK2 monolayers, as described
above. The mean virus titer was calculated for each group of
hamsters and is expressed as log10TCID50/gram of tissue.
To determine the level of protective efficacy, hamsters were
inoculated IN with 0.1 ml of L15 medium containing 106
TCID50 of rHPIV1-F, rHPIV1-G, rHPIV1-SH, or rHPIV1 or
105.3 HMPV. After 30 days, animals were immunized again with
either the empty vector (rHPIV1) or with a second, higher dose
of the vector bearing the HMPV glycoprotein (see Table 1).
Serum samples were collected before the first infection and 26
days after the second immunization (day 56). On day 58, animals
were challenged by IN administration of 105.5 TCID50 of HMPV
in a 0.1 ml inoculum. Nasal turbinates and lungs were harvested
4 days later, and the titer of virus in each tissue homogenate was
determined as described above.
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